All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
#IACH2024
Bookmark this article
To update you on the exciting content presented at the 7th Annual Meeting of the International Academy for Clinical Hematology (IACH) 2024, we have collated our social media coverage. Catch up with our posts relating to GvHD below.
CONGRESS | #IACH2024@AnnalisaRugger1, @SanRaffaeleMI, opens the transplantation session by discussing how to optimize the selection of stem cell source and donor, considering patient and disease related factors, preparative regimens and #GvHD prophylaxis, and donor related… pic.twitter.com/sYAiuIianZ
— GvHD Hub (@gvhd_hub) September 19, 2024
CONGRESS | @TheIACH #IACH2024| PRESENTATION
— GvHD Hub (@gvhd_hub) September 19, 2024
Zinaida Perić @zina_peric @UniRijeka discusses the prevention and management of long-term complications in patients with chronic GvHD.
They provide a roadmap for the prevention of long-term complications and highlight future directions,… pic.twitter.com/bvF3ULQXkM
CONGRESS | @TheIACH #IACH2024| PRESENTATION
— GvHD Hub (@gvhd_hub) September 19, 2024
Mohamad Mohty @Mohty_EBMT @HopSaintAntoine @Sorbonne_Univ_ shares insights on the treatment of patients with chronic GvHD.
They discuss treatment options, and highlight key data from the REACH3 and ROCKstar trials.
Follow our live feed… pic.twitter.com/K1xmUZLLM4
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— GvHD Hub (@gvhd_hub) September 19, 2024
Arnon Nagler @nagler_EBMT, @TelAvivUni, discusses optimal choice of conditioning regimen for AML, covering reduced intensity and myeloablative approaches, as well as combination and sequential protocols. He also mentions that… pic.twitter.com/eEklC132L3
CONGRESS | @TheIACH #IACH2024 | PRESENTATION
— GvHD Hub (@gvhd_hub) September 19, 2024
María Queralt Salas @QueraltSalas, @hospitalclinic, provides an overview of optimal #GvHD prophylaxis to prevent the development of clinically significant GvHD, while preserving sufficient immune responsiveness to maintain beneficial… pic.twitter.com/H4UcY67PTl
CONGRESS | @TheIACH #IACH2024 | PRESENTATION@Florent_Malard, @Sorbonne_Univ_, talks about diagnosis and management of acute #GvHD. Steroid-based treatments remain the first-line option for aGvHD. Ruxolitinib is the new standard for SR aGvHD, however it is ineffective in 40% of… pic.twitter.com/NE2IstuYI7
— GvHD Hub (@gvhd_hub) September 19, 2024
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox